Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, ...

The MHRA has approved aumolertinib for adult patients with non-small cell lung cancer (NSCLC), following a groundbreaking ...

Discover the major highlights from ASCO 2025, according to researchers and drug developers who attended the convention.

Combination treatment could also benefit patients with lung, bowel, pancreatic and other solid cancers who don’t respond to ...

Paclitaxel is indicated for the treatment of metastatic breast cancer, metastatic adenocarcinoma of the pancreas and locally ...

Shares of Summit Therapeutics SMMT tanked nearly 31% on Friday after it reported mixed results from the phase III HARMONi ...

Among the lung cancer population with EGFR mutations, patients with insertions at exon 20 (ex20ins) represent a significant unmet need segment. These patients often have poorer outcomes compared to ...

The addition of low-intensity electric tumor treating fields (TTFields) therapy to first-line standard chemotherapy was ...

Summit Therapeutics Inc. has recently reported positive topline results from the phase III clinical trial, Harmoni, ...

HUTCHMED will host a webcast to discuss the data presented at the ASCO Annual Meeting at 8:30 -9:00 am HKT on Tuesday, June 3, 2025 (8:30 - 9:00 pm EDT on June 2, 2025). The event will be held in ...

Manmeet Ahluwalia, MD, MBA, FASCO, chief of medical oncology, chief scientific officer, and deputy director of the Miami ...